How is abbvie preparing for teflaro's patent expiration?

AbbVie owns the Teflaro (ceftaroline fosamil) franchise, a result of its corporate acquisitions over the years. Publicly disclosed plans specifically about Teflaro’s patent expiration are not usually broken out in detail, but pharma companies typically pursue several common lifecycle-management strategies as exclusivity winds down. For AbbVie and Teflaro, potential approaches would include:

- Lifecycle patents and protection
- Filing additional patents around formulations, salts, polymorphs, or manufacturing processes.
- Patents on new or expanded methods of use (e.g., additional indications or dosing regimens).

- Regulatory and labeling expansions
- Seeking new or expanded indications (e.g., pediatric labeling, additional infection types) to extend clinical protection.
- Gaining approvals in key markets outside the U.S. where data exclusivity and market protection can differ.

- Pipeline and future-proofing
- Investing in next-generation cephalosporins or other antibiotic programs to replace or complement Teflaro revenue as exclusivity ends.
- Exploring combination therapies or companion diagnostics that extend the overall value proposition.

- Commercial and market strategies
- Strengthening hospital-market positioning and stewardship engagement to preserve use in high-need areas (MRSA and resistant infections).
- Geographic expansion and distribution arrangements to maximize remaining value where competition may be less intense.
- Pricing, reimbursement, and supply-chain strategies to maintain profitability during transition periods.

- Strategic partnerships or divestitures
- Collaborations or licensing deals for non-core markets or to co-develop new antibiotics, which can help manage the portfolio around patent cliffs.

If you’d like, I can look for the latest public statements, investor presentations, or patent-status updates to give you a more concrete snapshot of AbbVie’s current posture around Teflaro.